Ketorolac Doc Generici (Ketorolac Trometamol)

Ketorolac Trometamol is an NSAID that reduces pain by inhibiting cyclooxygenase-mediated prostaglandin synthesis.

• Moderate to severe acute pain: provides rapid analgesia for pain requiring opioid‑level relief.
• Postoperative pain: helps control pain after surgical procedures, facilitating early mobilization.
• Musculoskeletal or renal colic pain: offers short‑term relief when other analgesics are insufficient.

• Ketorolac Trometamol exerts its effect by non‑selectively inhibiting cyclooxygenase‑1 (COX‑1) and cyclooxygenase‑2 (COX‑2) enzymes, which blocks the conversion of arachidonic acid to prostaglandins. The reduction in prostaglandin synthesis diminishes peripheral sensitization and inflammatory mediators, leading to decreased pain perception and inflammation. By lowering prostaglandin levels in the central nervous system, it also reduces the amplification of nociceptive signals, contributing to its analgesic potency.

Ketorolac Trometamol may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dyspepsia or abdominal discomfort.
• Nausea or vomiting.
• Headache.
• Dizziness.
• Transient increase in serum creatinine.
• Mild elevation of blood pressure.

Serious or Rare Side Effects

• Gastrointestinal bleeding or ulcer perforation.
• Severe renal impairment or acute kidney injury.
• Anaphylactic or severe hypersensitivity reactions.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiovascular thrombotic events such as myocardial infarction.
• Severe hepatic dysfunction.

Before prescribing Ketorolac Doc Generici, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

• Renal impairment: avoid or use with caution in patients with reduced kidney function.
• Gastrointestinal risk: assess history of ulcers or bleeding before use.
• Cardiovascular caution: monitor patients with hypertension or heart disease.
• Pregnancy and lactation: contraindicated unless benefits outweigh risks; safety not established.
• Concomitant anticoagulants: increase bleeding risk; evaluate necessity.
• Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Ketorolac may interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): heightened bleeding risk.
• Other NSAIDs or aspirin: additive gastrointestinal toxicity.
• Selective serotonin reuptake inhibitors (SSRIs): increased bleeding potential.
• Lithium: reduced renal clearance leading to toxicity.
• Methotrexate: impaired elimination, risk of toxicity.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may reduce renal function.
• Diuretics: potential for renal impairment.
• Corticosteroids: enhanced ulcer risk.
• Alcohol: may increase gastric irritation.
• Beta‑blockers: may blunt antihypertensive effect.